Sichuan Kelun-Biotech Announces New H Shares Placing and Articles Amendment

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has entered into a Placing Agreement to issue 5,918,000 new H Shares at HK$331.8 per share, aiming to raise approximately HK$1,943.0 million. The proceeds will be used to advance R&D, enhance technology capabilities, and support corporate purposes. The company also plans amendments to its Articles of Association to reflect changes in capital structure post-placing, with no further shareholder approval needed.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical industry. The company focuses on research and development, clinical trials, registration filings, manufacturing, and commercialization of biopharmaceutical products, with an emphasis on enhancing internal R&D capabilities and expanding its product pipeline.

Average Trading Volume: 707,685

Technical Sentiment Signal: Buy

Current Market Cap: HK$72.5B

For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.